Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
This is an open-label multicenter Phase 1/2 dose escalation study, evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of the novel BCL-2 inhibitor ZN-d5 and Wee1 inhibitor ZN-c3 in subjects with AML.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults with AML (including secondary or therapy-related), relapsed from or refractory to one or more prior lines of therapy, which may include venetoclax except in Expansion Cohort A
ECOG performance status score ≤2.
Projected life expectancy of at least 12 weeks.
Estimated glomerular filtration rate ≥60 mL/min
Women of childbearing potential must not be pregnant and must use effective birth control during the study and for 6 months after the last dose of study drugs.
Men must agree to use a condom when having intercourse during the study and for 3 months after the last dose of study drugs.
You may not be if
Known active CNS involvement
Diagnosis of acute promyelocytic leukemia.
Peripheral blast count of \>25 × 109/L (cytoreduction permitted).
Adequate washout from prior therapy including hematopoietic stem cell transplant and recovery from prior treatment-related toxicities to Grade 2 or lower
Significant cardiovascular disease
Corrected QT interval (QTc) of \>480 msec
Active hepatitis B or hepatitis C infection
Concurrent treatment with strong CYP3A inhibitors or strong or moderate CYP3A inducers
Clareo Health | Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
